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Metastasis of cancer to distal sites is associated with 
poor patient prognosis and is the foremost cause of 
cancer- related death1, with approximately 90% of 
patients who succumb to cancer dying of metastatic dis-
ease2. Despite the advent of effective immuno therapies 
within the past decade, the majority of patients with 
advanced- stage and/or high- risk cancers continue to die 
as a direct result of metastatic disease or owing to com-
plications of its treatment3. Indeed, improvements in 
the survival of patients with cancer over time have not 
equally benefited those with metastatic disease4.
Nevertheless, most standard- of-care treatments 
and new molecularly targeted therapies, including 
immunotherapies, were developed on the basis of ini-
tial evidence of anticancer activity — either direct or 
via immune system engagement — obtained in pre-
clinical studies with tumorigenesis and/or primary 
growth, not metastatic activity, as the main end points. 
Similarly, clinical drug development generally relies 
on the demonstration of tumour shrinkage accord-
ing to the radiological Response Evaluation Criteria 
for Solid Tumors (RECIST)5,6, with confirmatory improve-
ments in clinical outcomes, ignoring the ability to inhibit 
metastasis. Only after clinically meaningful tumour 
responses and/or improvements in patient survival have 
been demonstrated in the metastatic setting will the drug 
be tested in adjuvant trials, with the aim of preventing 
or delaying the development of overt metastatic disease. 
Consequently, a paucity of preclinical discovery and 
thus clinical development exists for agents targeting the 
biological mechanisms underlying the metastatic process.
An urgent need remains for novel therapeutic strat-
egies and agents that prevent the establishment of and/or 
tissue colonization by metastases, which ultimately 
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Abstract | Most cancer- related deaths are a result of metastasis, and thus the importance of this 
process as a target of therapy cannot be understated. By asking ‘how can we effectively treat 
cancer?’, we do not capture the complexity of a disease encompassing >200 different cancer 
types — many consisting of multiple subtypes — with considerable intratumoural heterogeneity , 
which can result in variable responses to a specific therapy. Moreover, we have much less 
information on the pathophysiological characteristics of metastases than is available for the 
primary tumour. Most disseminated tumour cells that arrive in distant tissues, surrounded by 
unfamiliar cells and a foreign microenvironment, are likely to die; however, those that survive can 
generate metastatic tumours with a markedly different biology from that of the primary tumour. 
To treat metastasis effectively , we must inhibit fundamental metastatic processes and develop 
specific preclinical and clinical strategies that do not rely on primary tumour responses.  
To address this crucial issue, Cancer Research UK and Cancer Therapeutics CRC Australia  
formed a Metastasis Working Group with representatives from not- for-profit, academic, 
government, industry and regulatory bodies in order to develop recommendations on how to 
tackle the challenges associated with treating (micro)metastatic disease. Herein, we describe 
the challenges identified as well as the proposed approaches for discovering and developing 
anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer.
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lead to organ failure, morbidity and death. In addition, 
new strategies must be developed to facilitate clinical 
testing of therapeutic agents with an anti- metastatic 
mechanism of action. To assist the cancer drug discov-
ery and development community in addressing this 
critical issue, Cancer Research UK (CRUK), Cancer 
Research Technology (CRT) and Cancer Therapeutics 
CRC Australia (CTx) formed a Metastasis Working 
Group with representatives from academia, indus-
try, government and regulatory bodies in order to 
develop recommendations on how to surmount the 
challenges associated with treating metastatic disease. 
This article provides an overview of these challenges 
and describes the Metastasis Working Group recom-
mendations on best practices for the discovery and 
develop ment of anticancer agents designed specifically 
to circumvent metastasis, with consideration given to 
their implementation in clinical trials.
Challenges
The development of new effective medicines that inter-
rupt the primary causes of metastasis is a daunting but 
important challenge. Mechanistically, metastatic tumour 
cells are genetically unstable, and in most cancers no 
single dominant pathway is likely to control metastasis7. 
Indeed, the signalling pathways driving metastasis can 
vary between primary and secondary tumours and 
between metastases that arise at different sites8. The target 
of translational research efforts is often an occult pop-
ulation of tumour cells disseminating from the primary 
tumour, sitting dormant in a sanctuary site or constituting 
a micrometastasis in a distant organ. Selection for clinical 
testing of candidate anti- metastatic agents that might have 
limited or no effect on conventional preclinical outcomes, 
such as primary tumour growth, is another key challenge. 
In addition, validated biomarkers that can be used to 
increase the efficiency of mechanistic experiments and 
accelerate drug development are rarely available.
Across all cancers, the extent to which tumour cells 
have left the primary tumour and established occult 
(micro)metastases before patient diagnosis is acknowl-
edged to be poorly characterized9,10. Tumour cells 
might become invasive early in cancer development, 
and thus prevention of dissemination from a primary 
tumour is unlikely to be a clinically successful strategy 
owing to the presence of pre- existing but undetected 
metastases; however, prevention of secondary metasta-
ses is a plausible rationale for intervention. Metastatic 
dissemination is a multistage process, and various points 
of intervention have been identified and credentialed 
at the preclinical level (Fig. 1). These include targeting 
the initial steps of invasion and migration away from the 
primary tumour, entry into the circulation (intravasa-
tion) and extravasation at a distant site. As with inva-
sion, traversal of the circulatory system might also be 
an early event in cancer development, leading to the 
proposal that drug development efforts should also take 
into consideration the abrogation of metastatic coloni-
zation — that is, the outgrowth of a lesion in a foreign 
environment. Several aspects of metastatic colonization 
are distinct from primary tumour formation and could 
influence drug development. Moreover, multiple stud-
ies have revealed that tumour cells colonizing distant 
organs can differ from those of the primary tumour in 
many respects10–13, revealing potential therapeutic tar-
gets. Changes in tissue microenvironments that facilitate 
metastatic colonization are incompletely characterized 
and might begin before the arrival of metastatic tumour 
cells14,15. Several approaches for targeting such secondary 
sites have been proposed. Intervening early to disrupt 
the ‘pre- metastatic niche’ is one potential strategy, while 
therapy to either maintain dormancy or induce the death 
of cells in micrometastatic lesions is another. Whereas 
metastases that are detected before commencement of 
first- line therapy can sometimes be treated using radi-
ation therapy, new and less deleterious therapies that 
are additive or synergistic with the standards of care are 
a priority for the treatment of occult metastatic disease.
Key points
•	metastasis is associated with a poor patient prognosis and is the foremost cause of 
cancer- related death, with approximately 90% of patients who succumb to cancer 
dying of metastatic disease.
•	metastasis is inherently complex, with different distant sites having a distinct and 
specific extracellular matrix and cellular composition compared with that of the 
originating site, and therefore metastases must be considered biologically different 
from the primary tumour.
•	The standard cancer drug discovery and development pathway, including that for 
molecularly targeted and immunotherapies, generally ignores the ability of 
experimental medicines to inhibit metastasis.
•	A wealth of potential preclinical targets for anti- metastatic drug discovery and 
development have already been identified but remain to be validated using 
appropriate preclinical models that reflect the pathogenesis of metastatic disease  
in patients.
•	Despite some successes in the treatment of bone metastases, following extensive 
analyses in preclinical models, multiple late- stage failures in clinical development 
have resulted in anti- metastatic drug development efforts being deprioritized by the 
pharmaceutical industry.
•	Successful development of effective anti- metastatic therapies will require the 
regulatory agencies to work together with researchers, drug developers and 
statisticians to redefine the clinical development paradigm in order to encourage 
development of this complex but high- potential category of oncology drugs.
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The metastatic cell is a single genetic entity derived 
from a mass of cells possessing extensive genetic heteroge-
neity and consequent plasticity8. The distant tissue site will 
also have a distinct and specific extracellular matrix and 
cellular composition compared with that of the tumour tis-
sue from which the metastatic cell originated. Metastases 
must therefore be considered biologically different 
from primary tumour cells, at least in the early stages of 
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Fig. 1 | Overview of metastasis. Metastasis is a complex multistep process, and the very concept of designing a metastasis- 
specific therapeutic must consider which part of the process is best to target. Given that metastases are derived mainly 
from invasive tumours, therapeutic efforts have often targeted the intrinsic invasive propensity of tumour cells150,151. 
Tumour cell production of angiogenic factors and TGFβ can activate endothelial cells and fibroblasts to remodel tissues and 
promote tumour cell invasion of stromal- modified spaces152. Targeting stromal elements in cancers remains an active area 
of research153–157. Intravasation of tumour cells is promoted by binding to macrophages that cause transient permeability in 
the vasculature158; thus, targeting tumour- associated macrophages might reduce the number of circulating tumour cells 
(CTCs)159. Multiple factors intrinsic to tumour cells (including epithelial- to-mesenchymal transition, production of proteases 
and migratory capacity) improve intravasation, often via effects on cell types including fibroblasts, neutrophils and 
macrophages160. Most tumour cells that enter the vasculature die as a result of hydrodynamic physical damage or leukocyte 
attack160. However, platelets can bind to and protect CTCs and improve their ability to establish secondary sites161. Platelet–
CTC aggregates settled at distant sites can release cytokines that attract granulocytes162; targeting platelets or granulocyte 
recruitment can prevent metastasis162. Additionally , abrogation of platelet–CTC binding, leading to a reduction in the 
number of circulating and potentially metastatic cells163, might explain the suppression of metastasis by aspirin in breast 
and prostate cancer models164. Survival and proliferation of newly deposited cancer cells in a metastatic site are arguably 
the most important stages of the metastatic process. Cancers with a propensity to metastasize do not grow in all organs, 
indicating that a limited number of organs provide a suitable stromal environment for their colonization. Preferred 
colonization sites, termed pre- metastatic niches, can be prepared in advance of the arrival of disseminated tumour cells 
through the actions of myeloid- derived suppressor cells (MDSCs) and tumour cell- derived extracellular vesicles (EVs), such 
as exosomes17,165. Whether this process can provide novel therapeutic targets to limit the arrest and survival of metastatic 
cells remains unclear, with development of EV- specific drugs, for example, creating a challenge166. Evidence also supports 
roles for neutrophils167,168 and MDSCs169 in metastatic colonization. Evasion of the antitumour immune response is another 
critical factor in metastatic colonization. No single tumour type seems to exhibit all these mechanisms; therefore, targeting 
any one stage of the metastatic process requires a tumour- specific understanding of the mechanisms involved.
outgrowth. Studies specifically designed to examine the 
biological development of metastases are not common, 
and if we hope to target metastases effectively, we must 
gain a more complete understanding of the underlying 
biology. This issue is complex, although some successes 
have already been achieved, for example, in understanding 
the processes of pancreatic cancer metastasis16,17.
Metastatic dormancy is defined by an unusually long 
disease- free interval (months, years or even decades 
depending on the cancer type) between removal or suc-
cessful therapy of the primary tumour and subsequent 
clinical relapse with disseminated disease. Metastatic 
dormancy can be achieved by many means. Tumour cells 
can exit from the cell cycle or balance their proliferation 
and apoptosis. Host cells can limit angiogenesis or alter 
anticancer immune responses, resulting in immuno-
editing (with an equilibrium between immune elimina-
tion and escape of tumour cells)18. Tumour cell dormancy 
also alters chemotherapeutic efficacy, either because the 
non- dividing cells are more resistant to such treatment19 
or because they are protected by cellular and extracellular 
components of their microenvironment20–22 (Fig. 2).
The optimal means of selecting patients with a pre-
dictable risk and rate of disease progression for enrolment 
in a clinical trial of an anti- metastatic agent remain largely 
unknown. This challenge is compounded by the inability 
to reliably quantify the prevalence and extent of occult 
metastatic disease at enrolment. Because adjuvant clinical 
trials are often conducted only after positive results have 
been obtained in early phase clinical studies involving 
patients with advanced- stage (metastatic) disease and 
require considerable funding, large numbers of patients 
and long follow- up durations to capture the primary out-
come measure (for example, disease- free survival (DFS)), 
new non- conventional clinical development approaches 
are needed. The clinical trial design might vary depending 
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Fig. 2 | Dormancy and the metastatic niche. Metastatic latency is more pronounced for certain types of cancer, notably 
breast and prostate cancer and melanoma170. The detection of disseminated tumour cells (DTCs) in bone marrow 
aspirates, obtained long after eradication of the primary tumour, verifies the presence of dormant tumour cells and is 
predictive of disease recurrence171–173. Dormant tumour cells are proposed to exist either as single cells in a state of cell 
cycle arrest or as small masses of cells that fail to expand into clinically detectable lesions, possibly owing to failure of 
angiogenesis, balanced rates of proliferation and apoptosis or effective immunosurveillance174. Cells derived from these 
clusters that are too small to be detected by normal clinical imaging are presumably the source of circulating tumour cells 
detected in some patients after successful treatment of the primary tumour. The metastatic niche is likely to vary between 
different organs, reflecting the tissue- specific nature of the microenvironment in which the DTC is located; extensive 
crosstalk occurs between the tumour cells, stromal cells and extracellular matrix components of the niche. Various niches 
have been proposed, including the perivascular niche associated with the vasculature22, the haematopoietic stem cell 
niche of the bone marrow175 and the osteoblastic niche in bone176. The factors that maintain tumour cell dormancy in these 
niches are starting to be unravelled, with different extracellular matrix components, cytokines and other proteins being 
implicated for different cancer types and niches. Far less is understood about how dormancy is broken, which could occur 
following failure of immunosurveillance, in response to inflammation triggered by trauma or an infection or perhaps as a 
result of ageing- related deficiencies in tissue homeostasis. With regard to therapy , the challenge is to decide whether the 
aim should be to retain the DTCs in a dormant state or, instead, to disrupt their niche and dormancy , thereby rendering 
them susceptible to apoptotic or anoikic death and/or to chemotherapy.
on the patient population, the dosing schema (maximum 
tolerated versus biologically effective dose, limited cycles 
versus maintenance therapy and scheduling in relation 
to standard- of-care therapy), the primary end points and 
the available biomarkers of activity. In most cases, such 
trials will also need to be initiated without a history of 
regulatory approval of the experimental agent.
Missteps and a home run
Several past efforts to target the mechanisms of tumour 
metastasis have resulted in failure. Matrix metallo-
proteinase (MMP) inhibitors were developed as anti- 
metastatic agents on the basis of their capacity to inhibit 
tissue invasion by tumour cells early in the metastatic 
cascade and their cytostatic activity in preclinical mod-
els23,24. Subsequent studies enabled a more nuanced 
understanding of the metastasis- promoting as well as 
the metastasis- limiting effects of the MMPs and revealed 
that several other proteases have overlapping functions25. 
The preclinical models used had limited relevance to 
the clinical testing scenario, with the experimental 
design typically involving initiation of MMP inhibitor 
treatment soon after tumour cell inoculation, to form 
either a primary tumour or experimental metastases. 
In this setting, the MMP inhibitors were shown to be 
effective26; however, in the clinic, MMP inhibitors were 
tested in patients with advanced- stage disease, usually 
with drug- resistant metastatic disease. As a result, these 
phase II and phase III clinical trials of MMP inhibitors 
failed to show strong signals of efficacy27,28. In addition, 
the early drugs had broad spectrum anti- protease activ-
ity and were characterized by serious adverse effects in 
patients26. Other examples of anti- metastatic agents for 
which promising preclinical activity has not been trans-
lated into clinical efficacy include cilengitide (targeting 
αvβ3 and αvβ5 integrins on angiogenic blood vessels)29, 
and dasatinib and saracatinib (targeting SRC and BCR–
ABL1)4. These late- stage failures in clinical development 
have resulted in major financial losses, leading to anti- 
metastatic drug development being deprioritized by the 
pharmaceutical industry.
Conversely, successes have been achieved in the treat-
ment of bone metastases, following extensive analyses in 
preclinical models, either with antibodies targeting recep-
tor activator of NF- κB ligand (RANKL; also known as 
TNFSF11) or with a class of drugs known as bisphospho-
nates. Both of these therapies interrupt the ‘vicious cycle’ 
of bone metastasis. The bone metastatic vicious cycle is 
a specific example of tumour cell–microenvironment 
interactions that are likely to occur at other metastatic 
sites (albeit via differing mechanisms). In bone, tumour 
cells produce factors that activate osteoblasts to produce 
RANKL, which activates osteoclasts that subsequently 
degrade bone, releasing a host of growth factors that 
stimulate metastatic colonization by tumour cells30. 
Denosumab is a humanized monoclonal antibody tar-
geting RANKL that has been shown in preclinical experi-
ments to bind with its target in the bones of healthy 
transgenic mice expressing chimeric mouse–human 
RANKL31. In initial clinical trials in the metastatic set-
ting, traditional tumour growth inhibition or survival 
end points were not used as outcome measures with 
this cytostatic agent; instead, a reduction in skeletal- 
related events (SREs) was the primary end point32,33. 
Deleterious SREs, such as a bone fracture from expan-
sion of an existing metastasis or a new metastasis, were 
essentially direct readouts of the extent of metastatic 
burden. Accordingly, patients with breast or prostate 
cancers were enrolled because they are prone to devel-
oping bone metastases. Significant reductions in the 
incidence of SREs in patients treated with denosumab 
compared with those who received standard care were 
observed for both types of cancer34,35. In men with 
bone- metastatic castration- resistant prostate cancer 
(CRPC), the median time to first on- study SRE with 
denosumab was 20.7 months versus 17.1 months with 
the bisphosphonate zoledronic acid (HR 0.82, 95% CI 
0.71–0.95; P = 0.0002 for non- inferiority; P = 0.008 for 
superiority)34. In women with advanced- stage breast 
cancer, denosumab was superior to zoledronic acid 
in delaying the time to first on- study SRE (HR 0.82, 
95% CI 0.71–0.95; P = 0.01) and also the time to first 
and subsequent on- study SREs (rate ratio 0.77, 95% 
CI 0.66–0.89; P = 0.001)35. Denosumab was then com-
pared with placebo in adjuvant trials and delayed initial 
bone metastasis in patients with CRPC by a median of 
4.2 months36. However, in placebo- controlled trials involv-
ing patients with breast cancer, adjuvant denosumab was 
associated with only a minor37 or no38 reduction in the 
DFS or overall survival (OS). The reasons for this dis-
parity between SREs and OS outcomes are not entirely 
clear but might reflect a shift in bone metabolism that 
reduces the incidence of SREs without direct effects on 
cancer progression.
The value of bisphosphonates in reducing bone 
resorption and bone metastasis through direct targeting 
of osteoclasts has been demonstrated in many preclini-
cal studies39. In addition, bisphosphonates have broader 
anticancer activity against metastatic lesions in visceral 
organs, possibly through inhibition of angiogenesis or 
through inhibition of M2-like macrophages in other 
tissues39,40. A meta- analysis of clinical trials using bis-
phosphonates, supported by earlier preclinical data, has 
demonstrated reduced bone metastases and prolonged 
OS, at least in postmenopausal women with early stage 
breast cancer41. No benefit of bisphosphonate treatment 
was observed for premenopausal women41.
Preclinical drug development
Target identification
Many targets with known or proposed roles in metasta-
sis could be candidates for drug development (Table 1). 
These potential targets have been identified on the basis 
of associations between gene targets (often mutated) 
and metastasis or poor survival in patients42,43, targeted 
manipulation of genes to alter metastasis in preclinical 
models44–46, functional genomic screens47–49 and drug 
repurposing efforts50. In addition to functional preclin-
ical experiments, evidence that the target is associated 
with metastasis in the human disease is required. For 
the development of a targeted therapy, such as a small 
molecule, a peptide or an antibody, knowledge of the 
biological activity of the target is essential for support-
ing development of a functional biomarker. Targets 
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Table 1 | Selected preclinical data for potential anti-metastatic therapies
Agent Target Preclinical dataa
Antibodies
Anti- CCL2 CCL2 (chemokine) Prevented mobilization of myeloid cells from the bone marrow 
to colorectal liver metastases and thereby reduced metastasis177
Anti- BMP6 BMP6 (TGFβ superfamily cytokine) Reduced osteoblastic bone metastasis from prostate cancer178
Anti- PTHrP PTHrP (hormone involved in bone vicious cycle) Reduced liver and bone metastasis of melanoma179
Anti- N-cadherin N- cadherin (mesenchymal cadherin) Reduced prostate cancer muscle invasion and induced tumour 
cell apoptosis180
Anti- CD24 CD24 (GPI- linked sialo- glycoprotein) Reduced lung metastasis of bladder cancer181
Anti- CDCP1 Protease cleavage site of CDCP1 Prevented lung metastasis by inducing poly(ADP- ribose) 
polymerase- mediated cell death182
Anti- TSPAN8 TSPAN8 (tumour- associated tetraspanin) Reduced metastasis of epithelial ovarian cancer183
Anti- MT1-MMP Membrane type 1 MMP Reduced lung metastasis of melanoma184
Small- molecule inhibitors
BL5923 CCR1 (CCL9 and/or CCL15 chemokine signalling) Inhibited liver metastasis of CRC by blocking recruitment  
of myeloid cells185
SD208 TGFβ receptor 1 Reduced melanoma and prostate bone metastasis and 
decreased progression of established lesions186,187
CCT129254 Multiple kinases (including ROCK , PI3K and AKT) Inhibited melanoma lung metastasis188
Zibotentan Endothelin 1 Prevented lung colonization by bladder cancer cells but had no 
effect on established metastases189
Debio 0719 Lysophosphatidic acid receptor 1 (fibrosis) Decreased lung and liver metastasis in breast cancer and 
induced tumour cell dormancy11
β- Aminopropionitrile Lysyl oxidases Prevented breast cancer metastasis but had no effect on existing 
lesions190
CCT365623 Lysyl oxidases Prevented metastasis of breast cancer191
CA-074 Cathepsin B inhibitor Prevention of bone metastasis and shrinkage of existing bone 
metastases in a breast cancer model192
Napabucasin Unclear (STAT3 and cancer stem cell pathways) Reduced metastasis of pancreatic and colon cancers193
HO-3867 Unclear (STAT3 signalling and reversion of mutant 
p53 to a wild- type phenotype)
Reduced metastasis of ovarian cancer194
IRAK inhibitor and 
ginsenosides
IRAK1 Reversed paclitaxel resistance and reduced metastasis of 
TNBC195
Bafetinib LYN and BCR–ABL1 Decreased liver metastasis in a breast cancer model196
KPT-6566 PIN1 (prolyl isomerase that regulates proline- 
directed kinase signalling)
Decreased lung metastasis of TNBC197
SF2523 Dual PI3K and BRD4 inhibitor (MYC- mediating 
factors)
Reduced regional colonic lymph node metastasis and shrank 
established metastases in pancreatic carcinoma model198
Nifuroxazide Unclear (STAT3 signalling) Inhibited lung and abdomen metastasis of CRC and shrank 
existing metastases199
AECHL-1 (triterpenoid) Unclear (alters cytoskeletal dynamics and inhibits 
NF- κB-mediated MAPK activity)
Decreased lung metastasis of TNBC200
CCG-203971 Unclear (inhibits the RHO–MRTF–SRF pathway) Decreased lung metastasis in melanoma model201
Regorafenib Multiple kinases (including angiogenic receptor 
tyrosine kinases)
Decreased lung metastasis of CRC (via activation of the  
protein tyrosine phosphatase SHP1) and shrank existing 
metastases202
GW3965 Liver X receptors Inhibited brain metastasis of melanoma and shrank existing 
lesions203
Low- dose paclitaxel Tubulin Decreased lung metastasis of cholangiocarcinoma  
(via reduced nuclear import of the calcium- binding  
protein S100A4)204
Selumetinib MEK Decreased lung metastasis of TNBC205
G2 Fascin (actin- bundling protein) Decreased lung metastases of breast cancer206
Zileuton Arachidonate 5-lipoxygenase Reduced spontaneous metastasis of MMTV- PyMT cells168
with strong correlations with metastasis but not pass-
ing the functional tests might serve as biomarkers of 
a response.
Preclinical modelling
Effective candidate identification relies on preclinical 
models that accurately recapitulate the disease pathogen-
esis in patients and, specifically, the particular process 
being targeted (that is, initial invasion, extravasation, 
the development of nascent metastases or metastatic 
outgrowth). Many commonly used preclinical tumour 
models are better suited for testing agents that have a 
direct antitumour effect, often on primary tumours, 
rather than clinically relevant effects on metastasis51,52. 
For numerous cancer types, the primary lesion can be 
well controlled by standard therapies (surgery, radio-
therapy and/or chemotherapy) — the challenge is to 
control the onset and growth of secondary lesions.
No single preclinical model exists that wholly reflects 
metastasis in patients with cancer. Several different 
preclinical models of the type of cancer under study 
should be used when testing the anti- metastatic activity 
of a new drug to account for the diversity of the dis-
ease in patients52. If a molecularly targeted therapy is 
to be tested, an ideal preclinical model is one in which 
the target molecule promotes one or more steps in the 
metastatic process within that preclinical model. For 
example, inducible expression of the transcription fac-
tor Twist- related protein 1 in mice can drive epithelial- 
to-mesenchymal transition and result in increased 
metastasis of squamous cell carcinoma53. Other exam-
ples include prevention of metastases through target-
ing of SRC expression in orthotopic mouse models of 
human pancreatic adenocarcinoma54 or dual pharma-
cological inhibition of MET and VEGFR2 (reF.55) in 
various tumour models and tumour cell lines, or trans-
genic mice in which mammary tumour development 
and metastasis are driven by the expression of HER2 
(reF.56) or E545K- mutant PIK3CA57. Examining drug 
efficacy in models with complex genetics, including in 
both metastatic driver and passenger pathways, can also 
be informative by reflecting the genomic complexity of 
patient tumours.
The fact that host tissues dictate the extent to which 
a tumour can metastasize is becoming increasingly evi-
dent. The tumour microenvironment is complex, var-
ies extensively in different organs and is influenced by 
tumour–host cell interactions, physical and metabolic 
changes, and secreted cytokines, chemokines and growth 
factors58. As well as influencing tumour growth directly, 
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Agent Target Preclinical dataa
Peptides
Bone metastasis- targeting 
peptide 78
Endoplasmic reticulum chaperone BiP Reduced outgrowth of established lung and bone 
micrometastases in an advanced- stage breast cancer model207
T22 CXCR4 (SDF1 chemokine signalling) Showed synergy with anti- CTL A-4 therapy in reducing the size 
of established melanoma metastases208
Ac- PhScN-NH2 α5β1 integrin (fibronectin receptor) Inhibited bone metastasis, disease progression and lung 
colonization in a breast cancer model and shrank established 
lesions209
Immunotherapies
MTDH DNA vaccine MTDH Induced T cell responses and prevented lung metastasis in a 
breast cancer model210
LMP1 DNA vaccine LMP1 viral antigen Inhibited TC-1 lung metastasis in vivo via targeting of EBV 
LMPs211
Others
Retinoic acid Retinoic acid receptor (inhibits cell adhesion) Inhibited melanoma lung metastasis by inhibiting tumour cell 
adhesion to the vascular endothelium and subendothelium212
IGF trap IGF1R Promoted apoptosis of colon and lung cancer cells in nascent 
liver metastases213
Ad.dcn (decorin- expressing 
oncolytic adenovirus)
Various (results in downregulation of MET,  
β- catenin and VEGFA)
Systemic delivery shrank established bone metastases of 
prostate cancer214
Cellax- DTX polymer 
(docetaxel–acetylated car-
boxymethylcellulose–PEG 
conjugate nanoparticles)
Tubulin (results in selective depletion of activated, 
cancer- associated fibroblasts)
Decreased development of pancreatic metastases215
N- acetylcysteine Reactive oxygen species (antioxidant) Inhibited liver metastasis of pancreatic cancer216
NM-NP-CFZ 
(neutrophil-mimicking- 
nanoparticles containing 
carfilzomib)
Inflammatory neutrophils Prevented early lung metastases and shrank established 
metastases in mammary carcinoma models217
CDCP1, CUB domain- containing protein 1; CRC, colorectal cancer ; CTL A-4, cytotoxic T lymphocyte antigen 4; EBV, Epstein–Barr virus; GPI, glycosylphosphatidy-
linositol; LMP, latent membrane protein; MMP, matrix metalloproteinase; MRTF, myocardin- related transcription factor ; MTDH, metadherin (also known as LYRIC); 
PEG, polyethylene glycol; SRF, serum response factor ; TNBC, triple- negative breast cancer. aUnless otherwise noted, the intervention was shown to prevent or 
delay the development of metastasis.
Table 1 (cont.) | Selected preclinical data for potential anti-metastatic therapies
these changes alter the capacity of the immune system 
to recognize and attack tumour cells59. These factors 
must be taken into account when selecting preclinical 
models in order to ensure that interventions are effective 
for the tumour type and/or organ of metastatic involve-
ment58. For example, in a mouse model of prostate can-
cer, androgen ablation (by castration) was demonstrated 
to result in bone loss and enhanced the growth of dis-
seminated tumour cells (DTCs) in the bone; however, 
detrimental exacerbation of bone metastasis could be 
overcome by administering bisphosphonates together 
with androgen ablation60.
No in vitro test adequately models the entire meta-
static process; therefore, in vivo modelling is essential. 
Generally, metastasis models consist of either mouse 
tumours in a syngeneic host, thereby allowing for full 
engagement of the immune system, or human tumours 
engrafted into immunosuppressed hosts52,61. Mammals 
other than mice, such as rats62, are used occasionally, as are 
non- mammalian hosts such as zebrafish63, Drosophila64 
and the chick embryo chorioallantoic membrane65.
Genetically engineered mouse models (GEMMs) 
use mice bearing oncogenes that initiate a primary 
tumour (quite often, multiple primary tumours), which 
in some cases progress to metastatic disease (for exam-
ple, the LSL- KrasG12D/+; LSL- Tp53R172H/+; Pdx1-Cre KPC 
GEMM used for preclinical studies of both pancreatic 
cancer prevention and therapy66). When murine trans-
plantable tumour models are used, cells can be intro-
duced, preferably at orthotopic sites, to initiate primary 
tumour growth and subsequent spontaneous metastasis. 
A major advantage of such mouse metastasis models is 
the presence of matched stromal tissues that can recapit-
ulate growth factor signalling and anticancer immune 
responses. Given the obvious and critical role of the host 
immune system in regulating metastasis58,59,67, models of 
murine tumours in immunocompetent syngeneic hosts 
should be included in the preclinical testing of any new 
therapeutic whenever possible.
Metastasis assays can also involve established can-
cer cell lines or tissues recovered directly from patients 
undergoing tumour biopsy sampling or resection. As 
opposed to a cell line that has drifted genomically during 
long- term culturing, patient- derived xenografts (PDXs) 
have the important advantage of more closely reflect-
ing the genomic profile of the original tumour. PDXs 
are also reported to metastasize to the same organs as 
metastases in the donor patient68–70. However, xenograft 
models obviously lack competent immune regulation 
(owing to the need to avoid immune- mediated destruc-
tion of the transplanted allogeneic tumour cells). The 
advent of even more severely immunocompromised 
mice, such as non- obese diabetic–severe combined 
immunodeficient (NOD–SCID) and NOD–SCID–
IL-2-receptor γ- chain-mutant (NSG) mice, has enabled 
a higher proportion of tumours to be established in such 
models, with more circulating tumour cells (CTCs) and 
metastases. However, in patients, tumours develop 
despite the presence of a competent immune system 
by evolving mechanisms to escape immune detection 
and/or destruction; therefore, various methods of incor-
porating a human immune system into these severely 
immunocompromised mice are the subject of active 
research61. CTCs isolated from 10 ml of blood have also 
been used to generate patient- derived CTC xenograft 
models (CDXs) and have several advantages over PDX 
models generated using tumour biopsy samples. These 
advantages include the development of tumours with a 
molecular profile generally similar to that of the primary 
tumour and single CDXs that respond to chemotherapy 
in the same way as the donor patient’s tumour; the ability 
to generate models for patients with tumours that are 
not amenable to biopsy sampling or surgery; and the use 
of a population of tumour cells that has already gained 
an invasive behaviour, reflecting intra- patient hetero-
geneity, and that can be used as a surrogate to study 
metastasis (reviewed in reF.71). Nevertheless, CDXs do 
have drawbacks, such as lack of a functional immune 
system, and can be challenging to establish for some 
tumour types.
Cell lines and dissociated murine tumours can also be 
injected haematogenously, intraperitoneally, intrasplen-
ically or by other routes to circumvent primary tumour 
formation. This scenario might be justified for types of 
cancer in which initial seeding of tumour cells at distant 
sites commonly occurs before diagnosis. Such ‘experi-
mental metastasis’ models offer the advantages of rapid 
metastatic progression and greater numbers of tumours, 
which can accelerate study throughput. However, these 
models might fail to recapitulate the aforementioned 
capacity of the primary tumour to fashion the pre- 
metastatic niche by releasing growth factors, cytokines, 
proteases and extracellular vesicles14,72,73 (Fig. 2).
Models with different sites of spontaneous metastatic 
dissemination that reflect the patterns of metastasis in 
patients are a further necessity for preclinical testing. 
The 4T1.2 mammary cancer model is an example of 
a mouse model that recapitulates the pattern of meta-
static spread of its human counterpart, with the primary 
tumour generating spontaneous metastases in the lymph 
nodes, lungs and bones — major sites of metastasis in 
patients with breast cancer45. Clearly, therapies will need 
to be tailored for metastatic lesions in different organs 
because the microenvironments of bone, liver and brain, 
for example, are very different and therefore confer dif-
ferent properties to the tumour cells that successfully 
colonize these organs. For example, treatment with the 
RANKL antagonist osteoprotegerin effectively controls 
bone metastases, but not metastasis to the lungs in a 
mouse model of metastatic breast cancer74.
In general, too few preclinical metastasis models are 
available to adequately replicate the substantial hetero-
geneity of metastases in patients. Ideal models should 
be orthotopic, immunocompetent and able to produce 
metastases within a few months. Several common types 
of cancer, including melanoma, breast cancer and pros-
tate cancer, can have a long latency — up to two decades 
between the initial treatment of the primary tumour 
and the development of distant metastases. For these 
cancers, evidence exists for very early dissemination 
of the tumour cells, even before diagnosis, followed by 
long periods of dormancy after extravasation into other 
tissues22,75–80 (Fig. 2). These findings and those of other 
similar studies emphasize the importance of developing 
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therapies that can prevent the outgrowth of DTCs or that 
result in the death of very slowly cycling cells. Preclinical 
models that mimic this metastatic dormancy phenotype 
need to be developed to facilitate testing of such thera-
pies and should incorporate current adjuvant treatments, 
such as hormone therapy for breast or prostate cancer. 
Current models involve the use of transplantable tumour 
cell lines with much delayed development of metastatic 
disease that becomes evident only after an extended time 
following successful resection of the primary tumour. 
Examples include the mammary tumour lines D2.OR81 
and D2.A1-GFP82 and HEp3 cells isolated from the 
lymph node of a patient with head and neck squamous 
cell carcinoma83. Thus, various important features need 
to be considered when developing preclinical models 
of metastasis suitable to evaluation of experimental 
anti- metastatic agents (box 1).
Preclinical outcome measures
Development of metastases in preclinical models can 
be monitored by non- invasive imaging methods (for 
example, bioluminescence or MRI), enabling kinetic 
studies of their development. Standard metastasis mod-
els use imaging, histological counts and/or a quanti-
tative measure of metastatic burden45 as primary end 
points, with survival as a secondary end point. Less 
often, other potentially important end points, such as 
rates of cell proliferation and apoptosis, microenviron-
mental alterations or immune infiltration are reported. 
This approach enables investigation of novel therapies 
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Box 1 | Validating a potential anti- metastatic agent using preclinical in vivo models
Animal models are required to provide mechanistic insights into the effects of experimental agents on the entire 
metastatic process and are conducted primarily in mice. multiple factors are important to consider when establishing the 
experimental design if a translational goal is anticipated.
Prevention of metastasis versus shrinkage of existing lesion
most preclinical metastasis experiments are focused on preventing the initial formation of a metastasis — tumour cells 
are injected into mice, and the experimental agent is delivered soon after and continuously, with the number and sizes of 
metastases quantified at the end point. The findings of such studies are more relevant to adjuvant trial designs given the 
close alignment of aims between the clinical setting and these models — that is, avoiding relapse owing to undetectable 
disease. even so, metastatic tumours can be allowed to grow to reflect a more advanced- stage cancer setting.
Spontaneous versus experimental metastasis
metastasis models in which neoplastic cells form a primary tumour and subsequently metastasize are the gold standard, 
but the low number of lesions produced over long periods of time is an important limitation; few such models exist. other 
experimental models use haematogenous or other routes of tumour cell delivery and enable interrogation of the final 
stage of metastasis: metastatic colonization.
The source of tumour cells
Cell lines are easier to use, but long- term culture can result in cell lines that do not accurately recapitulate the actual 
clinical disease biology. Genetically engineered models generally have low frequencies of metastases and might not 
reproduce the genomic diversity of human tumours. By contrast, patient- derived xenografts and spheroids have been 
reported to closely replicate the tumour heterogeneity and evolution and the clinical course70,149. ultimately, the use of 
multiple models is always preferable.
The animal (typically mice)
Given the increasing importance of immunotherapy, and the immune contributions to responses to standard therapies, 
use of syngeneic, immune- proficient mice is advisable. Indeed, multiple aspects of the microenvironment are 
contributors to the metastatic cascade and ideally should be considered in preclinical models.
Site of injection
Subcutaneous models should be avoided. For models of spontaneous metastasis, orthotopic injection of tumour cells  
is mandatory.
Site of metastasis
The sites of metastasis in the mouse model should reflect the characteristic sites of dissemination associated with the 
human disease being studied.
Prior chemotherapy or radiation therapy, or concurrent therapy
Any new therapeutic must be given in the context of approved standard treatments. The model can be used to assess 
whether the new therapy should replace the standard treatment, be combined with it or be used sequentially.
Likely combination therapies
The functional redundancy of the metastatic process ultimately mandates that drug combinations be developed.
Oral or intravenous dosing
When long- term drug administration is required, as in most metastasis prevention studies, oral dosing is imperative 
unless agents with long half- lives, such as monoclonal antibodies, are under development. other routes of administration 
should be considered only if they are used clinically for the cancer type under study.
Pharmacokinetics
Collaborate with a pharmacologist, collect serum samples and generate pharmacokinetic data.
Other end points
Whenever possible, use end points in animal studies that closely reflect clinically relevant end points, such as disease- free 
survival, quality of life and overall survival, rather than tumour growth curves alone.
but also the development of drug resistance that is 
associated with metastasis. Chemoresistance is often 
considered to be caused by gene mutations that negate 
the cytotoxic effects of therapy. Surprisingly, diverse 
metastasis pathways have been functionally implicated 
in chemoresistance in mouse models (Supplementary 
Box S1). Mechanistically, reductions in chemosen-
sitivity have often been associated with activation 
of metastatic pathways that provide survival cues to 
the tumour cells, enhance proliferative signalling or 
counter DNA damage84–86. These findings uncover an 
unexpected intersection between metastasis and drug 
resistance that could lead to rational combinations of 
anti- metastatic agents and chemotherapies or other 
cytotoxic agents in clinical trials. These studies offer a 
provocative translational hypothesis, although careful 
studies using clinically achievable drug doses, sched-
ules and combinations are needed in multiple preclinical 
model systems, including both chemotherapy- naive and 
chemoresistant models.
Another consideration when developing anti- 
metastatic therapies is whether to target tumour cells 
directly or indirectly by modifying the tumour micro-
environment to be more suppressive to tumour growth. 
A common argument for targeting host cells is their greater 
genomic stability, which might make the development 
of drug resistance mechanisms less likely. However, 
the tumour microenvironment is complex and differs 
between each organ in which metastases have been 
established. Although not always adequate to predict 
metastatic events, preclinical models can help to under-
stand the different host microenvironments and can be 
used to test therapies focused on site- specific metastasis. 
The unique microenvironment of bone provides the best 
example, relating to the aforementioned application of 
bisphosphonates and denosumab. In preclinical models 
of breast cancer bone metastasis, responses to bisphos-
phonates were found to be dependent on menopausal 
status: ovariectomized mice (mimicking a postmeno-
pausal state) had a greater tumour burden in bone than 
control mice (mimicking a premenopausal state) but 
responded well to the therapy, whereas tumour burden in 
control mice was unaffected87. Likewise, in patients with 
breast cancer participating in the AZURE trial (zole-
dronic acid in combination with standard adjuvant ther-
apy), a significant improvement in DFS (HR 0.75, 95% 
CI 0.59–0.96; P = 0.02) and OS (HR = 0.74, 95% CI 0.55–
0.98; P = 0.04) was obtained only in women who had 
been postmenopausal for >5 years at the commencement 
of the trial88.
Development of pharmacodynamic markers indica-
tive of drug activity must also be incorporated into pre-
clinical testing. In clinical trials, traditional end points of 
radiological tumour responses and survival are increas-
ingly inadequate. Thus, knowledge of whether the 
drug hits its intended target and how the tumour cells 
and/or tumour microenvironment respond is of growing 
importance. When designing experiments in animals, 
adequate consideration should be given to analyses that 
are achievable in patients — that is, liquid and/or tumour 
biopsy- based assessments and imaging. Circulating cell- 
free tumour DNA (ctDNA), tumour- derived exosomes 
or CTCs are increasingly common sources of phar-
macodynamic markers that can be tested in mice and 
patients89–94.
Comparisons with human tissues
Evidence of the activity of a prospective target using pre-
clinical models is necessary but is not sufficient: assess-
ment of relevance using clinical samples is imperative. 
Clinical evidence can be obtained retrospectively by 
analysing publicly available databases for the transcript 
of interest and assessing its prognostic and/or predictive 
value in a specified cohort of patients with cancer that 
has appropriate follow- up data. Such databases could 
also be used to identify potential predictive biomarkers 
for later study in clinical trials. Supplementing analyses 
with additional information, such as data on inactivation 
or mutations in genes specifically associated with meta-
stasis, could also help build evidence for a particular tar-
get. If adopted, this approach must be used with caution, 
given that genetic alterations recorded in large databases 
might provide less robust targets for anti- metastatic 
agents than for other anticancer therapies because many 
metastasis pathways involve alterations in gene expres-
sion rather than mutations95. Any correlations must be 
confirmed at the protein level in tumour samples from 
a large number of patients, typically using tissue micro-
arrays. For example, in preclinical models of spontane-
ous mammary tumour metastasis to bone, restoration of 
interferon regulatory factor 7 (IRF7) expression in the 
tumour cells did not alter primary tumour growth but 
did inhibit bone metastasis44. In a retrospective analysis 
of data from 855 samples from primary breast cancers, 
high expression of an IRF7 pathway gene signature was 
associated with reduced bone metastasis of breast cancer 
(HR 0.63, 95% CI 0.42–0.93; P = 0.021) but had no prog-
nostic value in predicting metastasis to visceral organs44. 
In tissue array analyses, IRF7 protein was detected in 
56% of primary tumours compared with 17% of dis-
tant metastases and in only 11% of bone metastases44. 
Prospective analyses can provide very strong evidence 
for potential therapeutic targets or biomarkers, but in the 
absence of the relevant cohorts for prospective analysis, 
appropriately designed prospective retrospective 
analyses can also generate good levels of evidence96.
Associations with non- coding RNA species can 
be assessed similarly through in situ hybridization in 
tissue samples. Metastatic biopsy samples are rarer 
than primary tumour specimens but are important for 
analyses of biomarker expression in the development 
of anti- metastatic therapies. Data must be interpreted 
with consideration of the patient’s prior treatments 
(or lack thereof ) in terms of consistency with the 
proposed clinical setting in which the therapy will 
be developed.
Drug properties
The desired pharmacological profile used to guide drug 
screening necessitates a shift from that typically accepted 
in an acute tumour shrinkage model to one of chronic, 
ideally oral administration — with the exception of a 
monoclonal antibody, for which monthly infusions 
might be considered feasible — with an appropriate 
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risk–benefit profile. Optimization of structure–activity 
relationships can be used to select lead drug candidates 
with a pharmacokinetic profile appropriate for chronic 
use. For example, drugs that have good oral absorption 
characteristics and effective distribution to target tis-
sues and are poor substrates for metabolic (cytochrome 
P450) enzymes in the liver (to avoid potential drug–
drug interactions) are suited to simple once daily oral 
administration over months or years.
In the cancer setting, specific characteristics of the 
target disease, such as the frequency of metastasis to 
the brain, must also be considered97–99. For the example 
of brain metastasis, drug properties that increase blood–
brain barrier permeability and reduce the potential for 
membrane efflux transporter elimination might be 
a priority. Toxicological structure alerts (toxicophores) 
need to be avoided in the development of any drug that 
is to be dosed chronically, particularly in elderly or frail 
patients who are likely to present with comorbidities, 
including reduced renal and liver function, or in patients 
who have previously been treated with multiple lines of 
anticancer therapy and are therefore likely to have a poor 
performance status. Avoidance of drugs that have high 
risk of hERG voltage- gated potassium channel blockade, 
which is associated with potentially fatal cardiotoxicity, 
is a special case in point100. Other pharmacological fea-
tures associated with on- target and off- target toxicities 
also need to be avoided, particularly the generation of 
reactive metabolites that can cause carcinogenicity and 
nonspecific cytotoxicity.
Clinical drug development
Overview
Designing clinical trials and identifying end points that 
reflect the prevention of metastatic disease and can 
meet regulatory authority expectations for evidence of 
clinically significant benefit are arguably the most crit-
ical barrier to the development of new anti- metastatic 
agents. Measuring a clinically meaningful outcome in a 
realistic time frame, without requiring the recruitment 
of overwhelming patient numbers, is a key aim. The 
paucity of putative anti- metastatic agents being tested 
in clinical trials bears testament to these barriers.
Chemotherapies, hormone therapies, molecularly 
targeted agents, immunotherapies and various combi-
nations thereof have produced responses and prolonged 
progression- free survival (PFS) and OS in the meta-
static setting but are insufficient to achieve cure in most 
patients. Some of these same treatments have prevented 
or delayed the development of overt metastatic disease in 
some (but not all) patients when administered to those 
without detectable metastases but in whom micro-
metastases are suspected. Examples include the use of 
combination chemotherapy in the perioperative set-
ting for bladder cancer101,102 and adjuvant tamoxifen for 
breast cancer103. This scenario has led to a drug develop-
ment pathway in which therapies likely to be effective in 
eliminating micrometastases are progressed to the adju-
vant setting only after they first demonstrate antitumour 
effects in patients with advanced- stage disease. Such an 
approach also assumes that the biology of the metastases 
is similar to that of the primary tumour, which is not 
universally true. This drug development paradigm is 
further reinforced by the need to manage the very large 
risks associated with trials in the adjuvant setting (for 
example, relating to the need for large cohorts, healthier 
populations and long durations for data maturity; the 
high costs; and the lack of safety data in patients with 
anticipated long- term survival) by first demonstrating 
activity and acceptable toxicity in trials involving smaller 
numbers of patients with more rapidly attainable end 
points. In other words, demonstrated efficacy in patients 
with pre- existing metastases has traditionally been the 
obligate gateway to adjuvant trials of interventions for 
metastasis prevention.
The ability to delay or prevent metastases has the 
potential to enormously improve the survival durations 
of patients with cancer and could even lead to cures. 
However, the opportunity presented by anti- metastatic 
drugs cannot be explored adequately using conventional 
drug development pathways because drugs without 
cytotoxic or clinically meaningful cytostatic effects in the 
patients with overt metastatic disease will never advance 
to adjuvant trials. This point is central to the rethinking 
of clinical trial designs for metastasis prevention, with 
the clinical use of potential anti- metastatic drugs falling 
into three possible scenarios.
Occult micrometastatic disease. A practical definition 
of micrometastatic disease is that which is suspected 
to be present at the time of treatment of the primary 
tumour but is not evident using conventional imaging 
and clinical examination. Micrometastases can some-
times be detected by other methods, such as in bone 
marrow aspirates using flow cytometry104, biochemical 
techniques (such as rising serum PSA levels in patients 
with prostate cancer105) or molecular assays for tumour- 
derived DNA (typically ctDNA in blood samples106). 
However, the predictive power of some of these tests 
is debatable, with questions remaining regarding their 
sensitivity and specificity107. Prospective randomized 
clinical studies in specific disease settings are required 
to examine the utility of these detection methods and 
thereby validate their use in guiding treatment deci-
sions. Patients with micrometastasis can be identified 
across many, if not most, types of cancer, providing 
important new opportunities for anti- metastatic ther-
apy. Occult micrometastatic disease might either be 
actively growing or dormant and how this difference 
might affect the choice and timing of therapy remains 
unclear. The detection of rising PSA levels in patients 
with no other evidence of disease after prior treatment 
of prostate cancer can be used as a platform for meta-
stasis prevention (NCT03119857), although many tri-
als simply use PSA metrics as a primary end point of 
treatment efficacy.
Tumours that cannot be removed surgically. In gen-
eral, the aim of cancer surgery is to remove the primary 
tumour in order to obtain optimal local disease control 
and prevent the subsequent development of metastatic 
disease. Often, however, tumour resection is not feasible 
— despite the absence of metastatic disease — because 
of the anatomical location of the tumour or the likely 
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inability of the individual patient to tolerate the pro-
posed surgery (for example, owing to an insufficient 
respiratory reserve to endure pneumonectomy or insuf-
ficient fitness for prolonged anaesthesia). In practice, 
management of these patients presents a substantial 
clinical challenge. The use of drugs to prevent meta-
static spread in addition to therapy to achieve local dis-
ease control (for example, by chemoradiation of locally 
advanced pancreatic cancer) is a potential approach to 
overcoming this challenge. This strategy could also be an 
alternative to tumour resection for patients in whom the 
morbidity and mortality associated with surgery would 
be better avoided. Another option for such patients arises 
from the emerging realization of the abscopal effects 
of radiotherapy — that local radiotherapy can lead to 
immune- mediated destruction of tumours outside the 
irradiated field108. Several clinical trials (NCT03323424, 
NCT03396471 and NCT02992912) are now testing the 
combination of local radiotherapy with immunotherapy 
to exacerbate the damage to overt metastatic lesions out-
side the radiation field109,110. If this hypothesis is proven, 
then the abscopal effect could potentially be harnessed 
for the management of micrometastatic disease to effect 
cures in future trials.
Patients at high risk of invasive malignancy. Metastasis 
is rare in the absence of an invasive primary tumour; 
thus, a strong clinical rationale exists for eliminating 
cancer in its pre- invasive state to prevent disseminated 
disease. Patients with discrete pre- invasive lesions might 
undergo major local therapy; for example, patients with 
non- invasive tumours of the bladder often undergo 
cystectomy111, and those with breast ductal carcinoma 
in  situ can undergo mastectomy112. Even for some 
pre- cancerous conditions, the established organ- wide 
risk of pre- invasive disease (and thus malignant trans-
formation) can warrant preventive surgery (such as 
pan- colectomy for familial polyposis) or regular sur-
veillance with a view to major surgery (such as Barrett 
oesophagus). In some cases, complete removal of all 
at- risk tissue is not possible (for example, in patients 
with urothelial carcinoma in situ). Indeed, existing 
treatments are already used to reduce the risk of pro-
gression in patients with pre- invasive neoplasia (such as 
intra- vesical Bacillus Calmette–Guerin (BCG) immuno-
therapy for those with urothelial carcinoma in situ) or a 
known risk of developing cancer (for example, tamoxifen 
for women with an inherited risk of breast cancer owing 
to BRCA mutations). However, these approaches often 
have a disappointing effect on survival outcomes113,114, 
and the agents themselves might not target the path-
ways that most potently drive the invasive phenotype. 
Furthermore, continuous long- term administration of 
potentially toxic agents can be required to maintain 
the chemopreventive effect, which might not be fea-
sible; for example, chemoprevention with retinoids in 
patients with pre- malignant head and neck tumours 
has been limited by poor tolerability (with the majority 
experiencing cheilitis, dry skin and conjunctivitis)115. 
Consequently, the opportunity to develop rationally 
targeted, more efficacious and better tolerated sys-
temic therapies in such patient populations is attractive. 
In this scenario, anti- invasion therapies might be the most 
useful anti- metastatic approach.
Challenges in clinical trial design
A dominant problem in each of the preceding scenar-
ios is that intervention is likely to be required years in 
advance of the clinically important event (predom-
inantly metastatic relapse or death). This latency pre-
sents substantial challenges for the design of statistically 
powered clinical trials that meet the regulatory standards 
for evidence. The main implications are both economic 
and clinical. Economically, the costs of trials with large 
cohorts and long follow- up durations are prohibitive, 
and the predicted return on investment is restricted 
by the potentially limited time remaining on a patent. 
Indeed, many current adjuvant therapies have come into 
routine use only after or near the time of patent expiry. 
For this reason, such studies are rarely industry funded. 
Clinically, the imperative is to make more rapid progress 
than this scenario allows.
The end points traditionally used in oncology clin-
ical trials present an additional challenge. End points 
for determining antitumour efficacy in patients with 
advanced- stage disease continue to be based on con-
ventional outcome measures including the objective 
response rate (ORR) based on reductions in tumour 
dimensions on cross- sectional imaging of established 
metastases, PFS and/or OS. Adjuvant trials typically have 
a primary end point of DFS. These indicators of efficacy 
either present a specific challenge to the timely devel-
opment of anti- metastatic therapy or are not applicable 
in the absence of lesions that are detectable on imaging. 
Biomarkers that enable the detection of disease pro-
gression earlier than is possible through imaging of new 
metastatic lesions are clearly desirable; however, the use 
of such markers might require prospective validation, 
compounding the time and financial requirements.
With these challenges in mind, several ways for-
ward are discernible. Owing to the plethora of potential 
drug candidates and the high costs of late- phase clinical 
studies, early clinical development must be maximized 
as follows. Anti- metastatic agents are unlikely to be sub-
stantially different from any other candidate anticancer 
drug in this regard, but early go versus no- go decisions 
will need to be based on robust mechanistic and other 
pharmacodynamic biomarkers rather than on the typical 
evidence of objective tumour responses in patients with 
advanced- stage disease. Given the essential favourable 
safety profile of these anti- metastatic drugs, efficient 
early phase clinical studies could feasibly be conducted 
in healthy volunteers; thus, the identification of bio-
markers that are evaluable in non- malignant tissues will 
be of crucial importance.
The appropriateness of the novel end points will need 
to be supported by community- derived data providing 
compelling evidence that regulatory authority require-
ments will be met. By their nature, the novel end points 
are likely to be context- specific. Nevertheless, exam-
ples are available of accepted surrogate end points that 
have been used successfully in clinical development of 
drugs targeting pre- invasive pathways. These examples 
include the use of progression from early stage to stage 
196 | mARCH 2019 | volume 16 www.nature.com/nrclinonc
C o n S e n S u S  S tat e m e n t
T2 disease in establishing the role of intravesical BCG for 
the treatment of high- risk non- muscle-invasive bladder 
cancer113 and the use of a reduction in the numbers of 
polyps in the development of celecoxib for chemopre-
vention in patients with familial polyposis coli116. Early 
approval, on the basis on surrogate end points, will 
then need to be followed by confirmation of the clinical 
benefit in registry- type post- marketing studies.
In February 2018, the FDA also accepted the sur-
rogate end point of metastasis- free survival in the 
first registration of apalutamide for the treatment of 
non- metastatic CRPC117. However, this end point was 
controversial118 because the use of conventional imag-
ing (with isotope bone scans and CT) to establish the 
metastasis- free state will certainly result in failures 
to identify metastases that might be detectable using 
novel imaging modalities, such as whole- body MRI119 
or 68Ga- prostate-specific membrane antigen- PET120. 
The use of these novel imaging techniques is unlikely 
to have changed the outcome of the trial (an imbalance 
between the arms in the incidence of MRI- detectable 
or PET- detectable metastatic disease seems unlikely); 
however, if patients had disease staging using these 
alternative, more sensitive imaging modalities, the con-
trol intervention (placebo alone) would have been inap-
propriate for the subset of patients with upstaging to 
metastatic disease, and thus the true therapeutic value 
of apalutamide might have been overstated. Hence, 
completion of dedicated studies to identify the true 
incidence of metastatic disease in particular patient 
populations might be necessary before such end points 
can be used to explore drugs with the specific aim of 
preventing metastasis.
Secondary prevention studies of metastasis are 
ongoing. In one such study (NCT03190967), patients 
with brain- metastatic breast cancer are being randomly 
assigned to receive metastasis prevention with the anti-
body–drug conjugate trastuzumab emtansine alone or 
in combination with metronomic temozolomide, with 
the primary objective of extending survival without 
new brain metastasis121. Similar end points are being 
explored in patients randomly assigned to a meta-
stasis preventive strategy or control treatment after sur-
gery for liver- limited metastatic colorectal cancer (for 
example, NCT03326791 and NCT00394992). Novel 
liquid biopsy assays of circulating tumour components, 
including ctDNA and CTCs, could also offer important 
opportunities for the development of biomarkers as new 
surrogate end points or intermediate markers to reduce 
the risk and accelerate the progress of anti- metastatic 
drug development (see the ‘Regulatory and registration 
pathways’ section)91,122–126.
Selecting populations at particularly high risk of hav-
ing an early clinical event at a somewhat predictable rate 
for inclusion in first proof- of-concept trials — similar 
to the enrolment of patients at high risk of metastatic 
recurrence in the aforementioned studies of secondary 
metastasis prevention strategies — is a key approach to 
accelerating the development of anti- metastatic drugs. 
A wealth of literature is available describing prognos-
tic factors that can help to identify such patients127,128; 
however, few studies have been completed prospectively, 
have incorporated independent validation cohorts 
or have used methodologies that can be accurately repeated 
and certified in diagnostic laboratories. The magnitude 
of metastatic risk is also an important consideration. 
Whether clinicians will feel comfortable designing a 
trial in a population with a 30% or 50% risk of meta-
stasis over a defined period is debatable. The discovery 
of novel biomarkers that can be used to estimate the 
risk of micrometastases is a research area that has not 
been adequately addressed to date, although the use of 
ctDNA- based approaches to molecularly define minimal 
residual disease (MRD) might provide opportunities in 
this regard. Subgroups of patients with an especially high 
risk of early distant metastases are clearly identifiable. 
Examples include those with limited- stage small- cell 
lung carcinoma129, locally advanced pancreatic ductal 
adenocarcinoma130 or colorectal cancer and resectable 
liver metastases131. These disease settings are attractive 
both commercially and clinically, although reliance on 
such populations for early go versus no- go decisions 
holds the risk that effective anti- metastatic drugs will 
be prematurely discarded. Specifically, these high- risk 
populations might not display any degree of micro-
metastatic dormancy. Furthermore, these patients do 
not present an opportunity to explore drugs targeting 
pre-invasive targets.
Another way to improve the efficiency of late- stage 
drug development is to include only patients with disease 
in which the aberrant pathway being targeted is known 
to be active. This approach has other clear advantages to 
patients in that it avoids exposure to the toxicities of such 
drugs in those who are unlikely to benefit and enables 
their prioritization to receive other treatments. Indeed, 
this concept of precision medicine is rapidly becoming 
mainstream in all areas of anticancer drug development. 
To enable application of these principles to the develop-
ment of anti- metastatic drugs, a full understanding of 
the link between the therapeutic target and the relevant 
subpopulation is vital, given that metastases are likely 
to have more complex and different drivers than those 
of the primary tumour. Heterogeneity between individ-
ual metastases adds an additional layer of complexity. 
Moreover, clinically applicable diagnostics should be 
developed in parallel with the drugs themselves. For 
some patients, however, time is of the essence in decid-
ing on the next therapy; thus, a requirement to schedule 
biopsy sampling and evaluate the specimen in an accred-
ited laboratory might present difficulties, particularly in 
the secondary metastatic setting, in which the oncologist 
and patient want to decide quickly on the next line of 
therapy (or trial participation). Conversely, in the post-
operative adjuvant setting, this time delay might not 
be clinically relevant while the patient recovers from 
the primary surgical management. Similarly, when the 
aim is to evaluate the novel agent in a maintenance set-
ting, the patient first needs to complete conventional 
postoperative systemic anticancer therapy.
Drugs that specifically target the processes of meta-
stasis have the potential to transform the care of the 
majority of patients with solid tumours, although such 
agents are unlikely to be used as their sole therapy. One 
can envisage that treatment of the primary tumour and 
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standard- of-care adjuvant therapy will remain the initial 
interventions, followed by potentially lifelong mainte-
nance therapy to prevent the growth of pre- existing 
(micro)metastases and/or to prevent further spread 
of metastases. Thus, one challenging but necessary aim of 
clinical trials will be to establish the optimal combina-
tion and sequencing of these therapies with other modal-
ities including surgery, radiotherapy, chemo therapy, 
molecularly targeted therapy and/or immunotherapy. 
The need to address the long- term toxicities of these 
drugs given the likely chronic duration of therapy is 
also essential.
Regulatory and registration pathways
Many promising mechanistic biological targets exist 
for metastasis prevention strategies (Table 1); however, 
clear and feasible regulatory pathways for anti- metastatic 
agents are lacking. Specifically, the lack of surrogate end 
points appropriate for determining clinical efficacy at an 
early stage of drug development makes anti- metastatic 
agents unattractive to developers when compared 
with drug classes with rapid and proven pathways 
to registration.
A primary disincentive for anti- metastatic agents is 
the de facto use of time- to-event end points, such as PFS 
or OS, to assess efficacy in early stage clinical research. 
These end points present a far greater logistical and 
financial hurdle than the short- term ORR end points 
used to assess almost all newly registered oncology 
agents. In the period of 2006–2016, the FDA approved 
180 oncology drugs (new and supplemental registra-
tions), including 41 accelerated approvals: most accel-
erated approvals (n = 37) were based on ORRs, with the 
remaining 4 approvals based on PFS using assessment 
criteria defined by indication- specific working groups132. 
The RECIST alone were used in the majority of stud-
ies that led to accelerated approvals. The RECIST and 
working group- derived criteria are standardized, well- 
defined and provide a rapid readout of objective tumour 
responses or disease progression5, whereas assessment 
criteria appropriate for anti- metastatic treatments are 
not standardized or clearly defined. These limitations 
are particularly problematic because the existing criteria 
designed for assessing objective responses or progression 
of solid tumours are unlikely to be of any use in assess-
ing anti- metastatic agents that might have little effect 
on primary tumours; additionally, in most cases, the 
patient will not have any detectable disease at the time of 
treatment with such drugs.
In the absence of regulatory precedent or standardi-
zation, individual product developers will be required to 
explore new surrogate end points without certainty that 
regulators will accept their clinical relevance. Fortune 
rarely favours the brave in drug development. Even 
with a significant increase in biologically relevant bone- 
metastasis-free survival durations (4.2 month prolon-
gation versus placebo, HR 0.85; P = 0.028) in 1,432 men 
with CRPC at high risk of developing bone metastases, 
the FDA denied an application for expansion of deno-
sumab use to an anti- metastatic indication in this dis-
ease133. The regulator cited that it was “unclear whether 
an improvement in bone- metastasis-free survival alone 
in patients with CRPC at high risk of bone metastases is 
an adequate measure of clinical benefit in support of new 
labelling claims for a new patient population” (ODAC 
Briefing Document BLA 125320/28 Denosumab 
(XGEVA), 2012, FDA)133. This example underscores the 
risk involved in developing anti- metastatic agents and 
highlights the need to complete robust validation of 
putative new end points concurrently with the clinical 
development of such agents134,135.
Many other surrogate end points and biomarkers 
specific to metastatic progression have been consid-
ered, including the use of time- to-metastasis end points 
in patients at high risk of metastasis121, residual CTCs, 
ctDNA, DTCs and circulating tumour exosomes91. 
However, turning these end points and biomarkers into 
validated surrogates that regulators will endorse as the 
basis for accelerated approvals will require a collabora-
tive approach to overcome the limitations of novel end 
points proposed by individual sponsors on an ad hoc 
basis125. These limitations include the high cost of bio-
marker development, the work required for refinement 
and standardization of test methods and the requirement 
for validation across comparable data sets and in suffi-
ciently large numbers of the target population to support 
statistically robust conclusions136.
Plasma ctDNA profiling has demonstrated prom-
ise in detecting MRD and discriminating patients with 
and without eventual clinical recurrence following 
surgery and/or adjuvant therapy, notably in breast can-
cer123,124,126,137 and non- small-cell lung cancer122. These 
findings emphasize the potential use of ctDNA profiling 
to select patients at high risk of relapse following comple-
tion of adjuvant therapy for add- on anti- metastatic strat-
egies, although these approaches remain in the research 
setting. Monitoring treatment response to immuno-
therapy using ctDNA- based liquid biopsy approaches 
might also be feasible93. Prospective, randomized trials 
are required to test whether persistent or rising ctDNA 
can be used as a surrogate for adjuvant therapy, along-
side development of standardized workflows enabling 
clinical implementation. The implementation of such a 
strategy is illustrated by the accelerated FDA approval of 
blinatumomab in 2018 for the treatment of patients with 
B cell precursor acute lymphoblastic leukaemia who are 
in first or second complete remission but have an MRD 
burden ≥0.1%, which occurred on the basis of an end 
point relating to the achievement of undetectable MRD 
using a high- sensitivity detection assay after one cycle 
of treatment138,139. In addition, a Clinical Laboratory 
Improvement Amendments (CLIA)-registered duplex 
ctDNA blood test for colorectal cancer recurrence has 
been available in the USA since 2016 for surveillance of 
patients after tumour resection140.
The lack of fixed criteria for drug developers is an 
unacceptable disincentive, the effects being sadly evi-
dent in the lack of any new chemical entity initially 
registered for the prevention of metastasis. We urge 
regulatory agencies to work with researchers, drug 
developers and statisticians to identify and define 
guidelines for surrogate end points in order to encour-
age development of this under- represented category of 
oncology drugs.
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Given that some anti- metastasis agents might be 
used in a preventive setting, the safety profile of such 
an Investigational Medicinal Product (IMP) will have 
to be much cleaner than those of standard anticancer 
agents. Proceeding to clinical trials even in the absence 
of adequate preclinical efficacy models might be accept-
able, although a strong rationale will be needed to sup-
port long- term administration of the IMP in a healthier 
population of patients with cancer. The acceptable safety 
profile will be different for IMPs aimed at suppressing 
and/or eradicating established metastatic lesions. The 
benefit–risk assessment should include a detailed dis-
cussion of standard treatments, the temporal relation-
ship with standard therapy (neoadjuvant, adjuvant or 
other applications), proposed safety monitoring and 
risk- minimization strategies; the potential for drug–
drug interactions and risks associated with possible 
delaying of standard therapy should be addressed.
Development of new biomarkers as surrogate end 
points should be guided by correlations with previously 
validated end points and/or clinically relevant parame-
ters (reviewed in reF.141). Companion diagnostics can 
be developed in parallel to the IMP and used for explor-
atory purposes. Once validated, the diagnostic can be 
used to dictate patient eligibility for trial participation 
and/or treatment assignment. In the USA, the FDA has 
provided guidance on validation of biomarkers for use 
in clinical development142, and in the European Union 
(EU), the European Medicines Agency has released guid-
ance for biomarker analysis of clinical trial samples143. 
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Box 2 | Summary of recommendations for the development of anti- metastatic therapies
Target identification and preclinical models
•	Clear evidence and understanding of the functional relevance and 
biological activity of the proposed target in metastasis in humans  
are essential.
•	Preclinical models must reflect the disease pathogenesis in patients; for 
example, the sites of metastasis should encompass the same or similar 
organs, and the target (or equivalent target in the model) must have the 
same role as in the human setting. multiple models should be used.
•	experimental conditions should be designed to reflect the standard of 
care in the clinical setting and the desired route of treatment 
administration.
•	Careful consideration should be given to the involvement of the immune 
system and role of chemoresistance within the models used.
Drug discovery and preclinical development
•	Anti- metastatic drugs are likely to be given via the oral route repeatedly 
over a prolonged period of time (perhaps years), necessitating a shift 
from the risk–benefit profile of traditional anticancer agents towards  
one with a considerably lower level of risk; the absorption, distribution, 
metabolism and excretion (ADme) profile of the drug should reflect  
this necessity.
•	Drugs that have liver metabolism liabilities and/or common drug–drug 
interactions, undergo enzymatic hydrolysis or are substrates of 
membrane efflux transporters should be avoided.
•	The pharmacokinetic parameters of the drug must be optimized to 
enable high levels of target exposure, including a high dissolution rate 
and good solubility and permeability.
•	lead clinical drug candidates should be tested in several different and, 
ideally, genomically complex models to account for diversity of the 
disease in patients.
•	Pharmacodynamic markers need to be developed that reflect drug 
activity and can be translated to the clinical setting.
•	Toxicology readouts should generally be cleaner than that often 
accepted for anticancer agents; for example, the drug should not result 
in blockade of heRG voltage- gated potassium channels nor generate 
reactive metabolites that can lead to downstream carcinogenicity or 
nonspecific toxicity.
Clinical development
•	Given the potential ethical issues surrounding the testing of 
experimental agents with an anti- metastatic mechanism, specifically 
relating to the very limited possibility of clinical benefit in patients with 
advanced- stage cancer, studies involving healthy volunteers should be 
considered as a first step in clinical testing.
•	early clinical development (ideally phase I expansion cohorts) should be 
focused on demonstrating proof of biological concept using validated 
pharmacodynamic markers relevant to the target and drug being tested; 
if healthy volunteers are enrolled in clinical trials, these markers must be 
measurable in non- malignant tissues and/or in blood.
•	Any companion diagnostics that might have to be developed  
in parallel to the experimental therapeutic and Conformité européene 
(Ce) marked (indicating a product that meets european union (eu)  
safety, health or environmental requirements and complies with eu  
legislation) can be used to guide treatment and/or trial enrolment 
decisions.
•	Depending on the mechanism of action of the agent being tested, 
window of opportunity studies could also be considered during early 
phase clinical development to enable direct assessment of the biological 
mechanism in established primary or metastatic tumours.
•	Alternate surrogate measures of clinical benefit, beyond traditional 
radiological criteria based on tumour shrinkage, are needed and will be 
dependent on the disease and setting being investigated; potential 
examples include end points based on time to appearance of new lesions 
and/or secondary lesions or levels of circulating tumour cells or cell- free 
tumour DNA.
•	Initial proof- of-concept clinical studies can be conducted in selected 
patient populations at high risk of an early clinical event, such as a new 
metastasis. Thus, before and during clinical development, expert advice 
from oncologists with experience working with such patient groups 
should be sought. moreover, the aberrant pathway under assessment 
should be confirmed as being active in this population.
•	In light of the points above, clinical development timelines longer than 
those associated with traditional anticancer drugs should be anticipated; 
early approval based on surrogate outcomes should be a key goal,  
when possible.
Regulatory pathways
•	ensure that a strong rationale is provided in regulatory submissions to 
support the long- term administration of the anti- metastatic agent in a 
population of healthier patients with cancer.
•	Given the current absence of regulatory precedent or standardization, 
exploration of new surrogate end points should be discussed with the 
appropriate regulator before embarking on and during clinical drug 
development.
•	If approval is given on the basis of short- term surrogate end points, a 
requirement to complete ‘sales revenue- funded’ phase Iv confirmatory 
studies with larger cohorts, longer follow- up durations and more 
traditional end points, such as overall survival, should be anticipated.
•	We urge regulatory agencies to work together with researchers, drug 
developers and statisticians to define guidelines on surrogate end points 
to encourage development of this complex but high- potential category 
of oncology drugs.
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For marketing any test in the EU, Conformité Européene 
(CE) marking is required, indicating that the product 
meets EU safety, health or environmental requirements 
and compliance with EU legislation.
Conclusions
Survival outcomes of patients with cancer have steadily 
improved since the advent of treatments including sur-
gery, chemotherapy, radiotherapy, molecularly targeted 
therapies and immunotherapy. Nevertheless, in most 
patients who die of cancer, death is directly attributa-
ble to metastasis and not to the primary tumour. 
We have highlighted that development of effective thera-
pies to treat and/or prevent metastatic disease requires 
a marked shift from the standard drug discovery and 
development paradigm.
Crucially, drug discovery programmes aimed at 
developing agents that specifically target metastasis 
should take into consideration the challenges and 
recommendations proposed herein; to facilitate such 
studies, we have provided summaries of our recommen-
dations (box 2) and overall development pathway (Fig. 3). 
Careful application of these lessons, learned from past 
failures, should maximize the probability of success in 
Drug discovery and preclinical 
development
• Oral drug
• Risk–beneﬁt proﬁle appropriate 
for chronic dosing
• Active in several different and 
relevant in vivo models
• Develop relevant PD markers 
• Optimized PK/PD profile
Target identification 
and preclinical models
• Functional relevance
• Should reﬂect human 
metastatic disease
• Experiments mimic 
clinical conditions
• Role of immune 
system
Provisional 
approval?
(Accelerated) clinical programme
• Phase I studies focused on improved 
safety, proof of biology (PD characteristics) 
and PK proﬁle in healthy volunteers; PD 
characteristics should be measureable in 
non-malignant tissue and/or blood
• Consider window-of-opportunity studies in 
patients with cancer or at-risk populations
• Efﬁcacy initially measured using surrogate 
end point in patients (identiﬁed using 
CE-marked diagnostics?)
• Be prepared for longer development 
timelines, or aim for approval based on 
surrogate outcomes
In-use continuous 
assessment
• Sales revenue-funded 
data collection
• Efﬁcacy based on 
traditional clinical 
survival outcomes
• Further safety 
information
Multidisciplinary collaboration to identify and validate new targets, predictive and surrogate biomarkers and end points
Target 
identification Registration
Drug
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Preclinical
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clinical trials
Phase III and/or
phase IV clinical 
trial data
Phase II
clinical trials
Discovery Translation
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Fig. 3 | Development pathway for anti- metastatic agents. The general process for development of anti- metastatic 
agents has the same fundamental basis as that used in the development of drugs with a direct antitumour mechanism of 
action, with some special considerations as highlighted in the figure and described as follows. In target identification and 
preclinical development, special consideration must be given to the functional relevance of the models being used, which 
should reflect human metastatic disease as much as possible; the role of the immune system in metastasis is a critical 
factor. The experimental conditions should also mimic those of the clinical setting. Drug discovery and subsequent 
preclinical testing strategies need to be designed to account for the fact that, in most cases, the anti- metastatic therapy 
under development will be given chronically in a healthier population of patients, such as those that have been cured of 
their primary disease but are at high risk of developing secondary tumours, necessitating oral administration and a risk–
benefit profile lacking key toxicity liabilities. Other considerations, such as activity in several different preclinical models, 
an optimized pharmacokinetic (PK) profile and development of pharmacodynamic (PD) markers suitable for use in the 
clinic, are common to all cancer drug discovery and development programmes. Given the favourable risk–benefit profile 
necessary for anti- metastatic agents, an accelerated development approach can be taken by conducting initial phase I 
studies in healthy volunteers rather than the classical populations with advanced- stage cancer. The key aims of  
these studies are to determine the safety , PK profile and PD characteristics (ensuring the putative biomarkers developed 
can be measured in non- malignant tissues) in order to provide an early go or no- go decision point and ensure that  
the drug has the intended biological effects. To gain rapid biological proof of concept in patients with cancer, window- 
of-opportunity studies, in which a dose of the anti- metastatic agent is given before surgery to examine PD effects, can  
be considered. If validated surrogate end points of clinical efficacy are available, these can be used to substantially  
reduce development timelines and, provided agreement has been reached with appropriate regulatory bodies, support 
provisional approval. If successfully executed, this regulatory strategy will avoid the protracted clinical development 
timelines that are one of the greatest barriers to the development of anti- metastatic drugs. Provided that provisional 
approval is given, regulatory bodies will require further in- use continuous assessment, typically in confirmatory phase IV 
studies that can be funded using ongoing sales revenue. The aim of these larger- cohort and much longer duration clinical 
trials is to confirm that a pre- defined level of clinical benefit is achieved according to more traditional outcomes, such as 
overall survival. If provisional approval has not been given by regulators, then costly (in terms of both finance and time) 
randomized controlled phase III studies in large cohorts will be necessary to gain approval on the basis of standard clinical 
outcome measures. CE, Conformité Européene.
the development of this drug class. Regardless, continued 
discussion of these issues is warranted.
Indeed, considerable challenges remain, not least 
regarding the currently limited ability to detect pre- 
existing micrometastatic disease at first diagnosis. 
Establishment of new detection methods such as the 
Metas- Chip approach144, which uses a microelectronic 
biochip to detect micrometastasis using small- volume 
tumour and lymph node samples, will be needed. This 
method requires biopsy samples consisting of live cells 
and is based on the principle of detecting the migra-
tory behaviour of tumour cells via their invasive capac-
ity to retract single human umbilical vein endothelial 
cells from electrical sensing traps. Clear limitations of 
such assays include the logistical challenges associated 
with obtaining high- quality live biopsy material in 
the standard hospital setting and the high probability 
of no tumour cells being present in the tissue sample. 
The development of enhanced imaging techniques 
with greater resolution and sensitivity than those cur-
rently available, and their translation to widespread 
clinical application, will also be vital. Some examples 
under investigation include high- contrast fluorescence 
detection145, multispectral optoacoustic tomography146, 
shortwave infrared emitting nanoprobes147 and novel 
MRI contrast agents148. An ability to detect micro meta-
stases, in addition to primary tumours and macro-
metastases, using these and other approaches will 
ensure that patients can be enrolled in clinical trials and 
assigned to appropriate treatment regimens.
Given the inherent additional complexity, timelines 
and potential cost of developing anti- metastatic agents, 
the support of regulators and the pharmaceutical indus-
try will be crucial for future success. If this support can 
be provided, the potential improvements in the welfare 
of patients with cancer cannot be understated.
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